...
首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis.
【24h】

D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis.

机译:D-二聚体和残余静脉阻塞是首次引发深静脉血栓形成的患者在抗凝治疗撤药期间和之后复发的危险因素。

获取原文
获取原文并翻译 | 示例

摘要

D-dimer and residual venous obstruction (RVO) have been separately shown to be risk factors for recurrent venous thromboembolism (VTE) after a first episode of unprovoked proximal deep-vein thrombosis (DVT). It was the objective of this study to assess the predictive value of D-dimer and residual vein obstruction (RVO), alone and in combination, for recurrence after provoked DVT of the lower limbs. A total of 296 consecutive patients with a first episode of symptomatic provoked proximal DVT were evaluated at a university hospital in Bologna, Italy. On the day of anticoagulation withdrawal (T0), RVO was determined by compression ultrasonography. D-dimer levels (cut-off: 500 ng/ml) were measured at T0 and after 30 +/-10 days (T1). The main outcome was recurrent VTE during a two-year follow-up. D-dimer was abnormal in 11.6% (32/276) and 31% (85/276) of subjects at T0 and at T1, respectively. RVO was present in 44.8% (132/294) of patients. Recurrence rate was 5.1% (15/296; 95% confidence interval [CI]: 3-8%; 3% patient-years; 95% CI: 2-5 %). An abnormal D-dimer either at T0 or at T1 was associated with an adjusted hazard ratio (HR) for recurrence of 4.2 (95% CI:1.2-14.2; p=0.02) and 3.8 (95%CI: 1.2-12.1; p=0.02), respectively, when compared with normal D-dimer. The HR for recurrence associated with RVO was not significant, and RVO did not increase the recurrence risk associated with an abnormal D-dimer either at T0 or T1. In conclusion, an abnormal D-dimer during vitamin K antagonist (VKA) treatment or at one month after VKA withdrawal is a risk factor for recurrence in patients with provoked DVT, while RVO at the time of anticoagulation withdrawal is not.
机译:D-二聚体和残余静脉阻塞(RVO)已被单独证明是在首发无因的近端深静脉血栓形成(DVT)后发生复发性静脉血栓栓塞(VTE)的危险因素。这项研究的目的是评估D-二聚体和残余静脉阻塞(RVO)单独或组合对下肢DVT诱发后复发的预测价值。在意大利博洛尼亚的一家大学医院对总共296例首发有症状的近端DVT症状的连续患者进行了评估。在抗凝停药当天(T0),通过压缩超声检查确定RVO。在T0和30 +/- 10天(T1)之后测量D-二聚体水平(截止:500 ng / ml)。主要结果是在两年的随访中再次发生VTE。在T0和T1分别有11.6%(32/276)和31%(85/276)的D-二聚体异常。 RVO患者占44.8%(132/294)。复发率为5.1%(15/296; 95%置信区间[CI]:3-8%; 3%患者-年; 95%CI:2-5%)。在T0或T1处异常的D-二聚体与调整的复发风险比(HR)相关(4.2(95%CI:1.2-14.2; p = 0.02)和3.8(95%CI:1.2-12.1; p)与正常的D-二聚体比较时= 0.02)。与RVO相关的复发的HR并不显着,并且RVO并没有增加与T0或T1时异常D-二聚体相关的复发风险。总之,在维生素K拮抗剂(VKA)治疗期间或停药后一个月内D-二聚体异常是诱发DVT的患者复发的危险因素,而在抗凝停药时RVO并非如此。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号